These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32485225)

  • 1. Old active ingredients in new medicinal products: is the regulatory path coherent with patients' expectations?
    Minghetti P; Musazzi UM; Casiraghi A; Rocco P
    Drug Discov Today; 2020 Aug; 25(8):1337-1347. PubMed ID: 32485225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory Aspects for Approval of Advanced Therapy Medicinal Products in the EU.
    Fürst-Ladani S; Bührer A; Fürst W; Schober-Ladani N
    Handb Exp Pharmacol; 2024; 284():367-387. PubMed ID: 37017789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Licensing of Orphan Medicinal Products-Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021.
    Naumann-Winter F; Wolter F; Hermes U; Malikova E; Lilienthal N; Meier T; Kalland ME; Magrelli A
    Front Pharmacol; 2022; 13():920336. PubMed ID: 36034814
    [No Abstract]   [Full Text] [Related]  

  • 4. Medicinal Product Regulation: Portugal׳s Framework.
    Herdeiro MT; Bastos PD; Teixeira-Rodrigues A; Roque F
    Clin Ther; 2016 Sep; 38(9):2118-2126.e2. PubMed ID: 27574988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The use of nanotechnology in medicinal products in the light of European Union law].
    Jurewicz M
    Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory exclusivities for medicinal products for human use in the EU.
    Schoonderbeek C; Jong B
    Pharm Pat Anal; 2016; 5(1):5-8. PubMed ID: 26674744
    [No Abstract]   [Full Text] [Related]  

  • 7. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [European Union regulatory and quality requirements for botanical drugs and their implications for Chinese herbal medicinal products development].
    Zhu YP
    Zhongguo Zhong Yao Za Zhi; 2017 Jun; 42(11):2187-2192. PubMed ID: 28822167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Harmonizing development, approval and access of drugs for rare diseases in Europe.].
    Costa E; Magrini N
    Recenti Prog Med; 2022; 113(7):407-410. PubMed ID: 35852074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European regulatory use and impact of subgroup evaluation in marketing authorisation applications.
    Tanniou J; Teerenstra S; Hassan S; Elferink A; van der Tweel I; Gispen-de Wied C; Roes KCB
    Drug Discov Today; 2017 Dec; 22(12):1760-1764. PubMed ID: 28943304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
    Martinac AI; Tomić S; Simicić M
    Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar biological medicinal products containing recombinant human growth hormone: European regulation.
    Pavlovic M; Girardin E; Kapetanovic L; Ho K; Trouvin JH
    Horm Res; 2008; 69(1):14-21. PubMed ID: 18059081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Requirements on efficacy of herbal medicinal products.
    Claeson P
    J Ethnopharmacol; 2014 Dec; 158 Pt B():463-6. PubMed ID: 25043782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marketing authorisations for unmet medical needs: A critical appraisal of regulatory pathways in the European Union.
    Manellari S; Musazzi UM; Rocco P; Minghetti P
    Int J Pharm; 2023 Jul; 642():123193. PubMed ID: 37394157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approval probabilities and regulatory review patterns for anticancer drugs in the European Union.
    Hartmann M; Mayer-Nicolai C; Pfaff O
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):112-21. PubMed ID: 23433721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel excipients - Regulatory challenges and perspectives - The EU insight.
    Kozarewicz P; Loftsson T
    Int J Pharm; 2018 Jul; 546(1-2):176-179. PubMed ID: 29792985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European regulation model for herbal medicine: The assessment of the EU monograph and the safety and efficacy evaluation in marketing authorization or registration in Member States.
    Qu L; Zou W; Wang Y; Wang M
    Phytomedicine; 2018 Mar; 42():219-225. PubMed ID: 29655689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.